PRECLINICAL IN VITRO AND IN VIVO PROFILE OF PXT3003, A NEW PROMISING THERAPEUTIC CANDIDATE FOR CMT1A

被引：0
|
作者：
Chumakov, I [1 ]
Nabirotchkin, S. [1 ]
Milet, A. [1 ]
Cholet, N. [1 ]
Primas, G. [1 ]
Graudens, E. [1 ]
Bertrand, V [1 ]
Mandel, J. [1 ]
Pereira, Y. [1 ]
Nave, K-A [2 ]
Guerassimenko, O. [1 ]
Vial, E. [1 ]
Guedj, M. [1 ]
Cohen, D. [1 ]
机构：
[1] Pharnext, Issy Les Moulineaux, France
[2] Max Planck Inst, Gottingen, Germany
来源：
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM | 2013年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：23 / 23
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of PXT3003 in patients with Charcot-Marie-Tooth type 1A: Results of PLEO-CMT, an international pivotal phase 3 trial
    Thomas, Florian P.
    Boutalbi, Youcef
    Fitoussi, Serge
    Rinaudo, Philippe
    Bertrand, Viviane
    Hajj, Rodolphe
    Nabirotchkin, Serguei
    Cohen, Daniel H.
    NEUROLOGY, 2019, 93 (05) : E530 - E530
  • [22] Baclofen, Naltrexone and Sorbitol all contribute to PXT3003-induced myelination and improve energy metabolism and degradation pathways altered in CMT1A DRG co-cultures
    Cholet, N.
    Boussicault, L.
    Laffaire, J.
    Malderez, C.
    Boscus, D.
    Primas, G.
    Nabirotchkin, S.
    Hajj, R.
    Cohen, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 190 - 190
  • [23] In vitro and in vivo profile of the preclinical candidate and MPS1 kinase inhibitor CCT289346
    Woodward, Hannah
    Innocenti, Paolo
    Cheung, Kwai-Ming J.
    Naud, Sebastien
    Faisal, Amir
    Mak, Grace W.
    Hayes, Angela
    O'Fee, Lisa
    Saville, Harry
    Brandon, Alexis De Haven
    Roberts, Jennie
    Box, Gary
    Valenti, Melanie
    Heneley, Alan T.
    Walsh, Katie
    Burke, Rosemary
    Eccles, Suzanne A.
    Raynaud, Florence I.
    Van Montfort, Rob L.
    Blagg, Julian
    Linardopoulos, Spiros
    Hoelder, Swen
    CANCER RESEARCH, 2018, 78 (13)
  • [24] MTBL0036, a New Promising Antidiabetic Drug Candidate: In Vivo Preclinical Studies
    El Hage, Maha
    Moinet, Gerard
    Ferrier, Bernard
    Nazaret, Remi
    Martin, Guy
    Conjard-Duplany, Agnes
    Baverel, Gabriel
    DIABETES, 2013, 62 : A307 - A307
  • [25] ARE GABA-B RECEPTOR LIGANDS OF THERAPEUTIC INTEREST FOR CMT1A? NEW INSIGHTS FOR DECIPHERING THEIR MECHANISMS OF ACTION
    Magnaghi, V
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2016, 21 (03) : 277 - 277
  • [26] HD047703, a New Promising Anti-Diabetic Drug Candidate: In Vivo Preclinical Studies
    Kim, SoRa
    Kim, Dae Hoon
    Kim, Young-Seok
    Ha, Tae-Young
    Yang, Jin
    Park, Soo Hyun
    Jeong, Kwang Won
    Rhee, Jae-Keol
    BIOMOLECULES & THERAPEUTICS, 2014, 22 (05) : 400 - 405
  • [27] Nintedanib as a new therapeutic agent for Duchenne muscular dystrophy: preclinical in vitro and in vivo studies
    Pinol, P.
    Fernandez-Simon, E.
    Suarez, X.
    de Luna, N.
    Molins, A.
    de Oliva, N.
    Martinez, A.
    Escudero, L.
    Sanchez, D.
    Navarro, X.
    Illa, I.
    Gallardo, E.
    Diaz-Manera, J.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S191 - S191
  • [28] Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis
    Rafaella R. Costa
    João A. Oliveira-da-Silva
    Thiago A. R. Reis
    Grasiele S. V. Tavares
    Débora V. C. Mendonça
    Camila S. Freitas
    Daniela P. Lage
    Vívian T. Martins
    Luciana M. R. Antinarelli
    Amanda S. Machado
    Raquel S. Bandeira
    Fernanda Ludolf
    Thaís T. O. Santos
    Rory C. F. Brito
    Maria V. Humbert
    Daniel Menezes-Souza
    Mariana C. Duarte
    Miguel A. Chávez-Fumagalli
    Bruno M. Roatt
    Elaine S. Coimbra
    Eduardo A. F. Coelho
    Medical Microbiology and Immunology, 2021, 210 : 133 - 147
  • [29] Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis
    Costa, Rafaella R.
    Oliveira-da-Silva, Joao A.
    Reis, Thiago A. R.
    Tavares, Grasiele S. V.
    Mendonca, Debora V. C.
    Freitas, Camila S.
    Lage, Daniela P.
    Martins, Vivian T.
    Antinarelli, Luciana M. R.
    Machado, Amanda S.
    Bandeira, Raquel S.
    Ludolf, Fernanda
    Santos, Thais T. O.
    Brito, Rory C. F.
    Humbert, Maria V.
    Menezes-Souza, Daniel
    Duarte, Mariana C.
    Chavez-Fumagalli, Miguel A.
    Roatt, Bruno M.
    Coimbra, Elaine S.
    Coelho, Eduardo A. F.
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2021, 210 (2-3) : 133 - 147
  • [30] Analytical assay development for TGT-001, AAV-CRISPR-based therapeutic candidate for Charcot-Marie-Tooth type 1A (CMT1A) : AAV titration using ddPCR and a quantitative in vitro potency assay for AAV vectors encoding CRISPR
    Go, N. Y.
    Oh, H. K.
    Ahn, C. H.
    Lee, J. Y.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A115 - A115
12345